Fig. 1From: Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylationStem cell marker expression in glioblastoma. Expression of SOX2, CD133, and NES as determined by IHC, was stratified into high and low levels of each stem cell marker. High levels of expression of SOX2 A, CD133 B, and NES C are shown in the upper panels, and low (non-zero) levels of SOX2 D, CD133 E, and NES F are shown in the lower panelsBack to article page